Research finds surge in using weight reduction medicine amongst bariatric surgical procedure sufferers

New analysis findings present a major improve in using weight reduction medicine amongst sufferers present process metabolic and bariatric surgical procedure, signaling an evolution within the administration of weight problems and Kind 2 diabetes.

The analysis can be offered on the American Faculty of Surgeons (ACS) Medical Congress 2025 in Chicago, October 4-7. 

There isn’t any one-size-fits-all method to treating weight problems, metabolic syndrome, or diabetes and its associated situations. We’re coming into a brand new world of multidisciplinary care pathways and a brand new frontier of weight administration that’s necessary for sufferers and surgeons to consider.”

Patrick J. Sweigert, MD, senior writer of the research and a bariatric and foregut surgeon, The Ohio State College Wexner Medical Heart, Columbus, Ohio

The analysis crew carried out a cross-sectional research glucagon-like peptide-1 receptor agonists (GLP-1s) semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) amongst sufferers present process metabolic and bariatric surgical procedure. Dr. Sweigert and colleagues analyzed practically 365,000 sufferers who underwent major metabolic and bariatric surgical procedure between 2018 and 2024. They used the Epic Cosmos database, which incorporates greater than 300 million affected person data from establishments throughout the nation, to look at prescription patterns for semaglutide and tirzepatide, two of the latest GLP-1s to hit the market.

Key findings

• Preliminary findings point out the proportion of sufferers receiving at the very least one GLP-1 prescription within the 12 months main as much as surgical procedure elevated from 1.8% within the first quarter of 2020 to 29.4% within the fourth quarter of 2024 – a sixteenfold rise. Use surged throughout sufferers with and with out diabetes, underscoring the increasing function of those medicines in weight problems remedy, impartial of diabetes standing.

• Amongst sufferers with out Kind 2 diabetes, preoperative GLP-1 use rose elevenfold over the previous three years-from 2.1% within the first quarter of 2022 to 23.2% within the fourth quarter of 2024. By comparability, use amongst sufferers with Kind 2 diabetes elevated fourfold, from 11.3% to 45.2% over the identical interval.

  
  
  

The median age of sufferers was 43 years, the median preoperative physique mass index (BMI) of those sufferers was 46. Ladies made up 80% of the pattern, and 33% had a prognosis of Kind 2 diabetes.

Lead writer Stefanie C. Rohde, MD, a normal surgical procedure resident at The Ohio State College Wexner Medical Heart, famous that the findings mirror a shift in how bariatric surgical procedure candidates understand their remedy choices.

“Whereas sufferers beforehand believed that they had to decide on between GLP-1 receptor agonists and surgical procedure, we’re now seeing that individuals are utilizing each,” Dr. Rohde mentioned. “We all know that sufferers can use GLP-1s after bariatric surgical procedure to amplify their weight reduction. However all of that is nonetheless very new by way of tips on how to handle sufferers successfully.”

Going ahead, she added, real-world knowledge equivalent to that from Epic Cosmos can assist the event of evidence-based tips for when to begin, mix, or transition between remedy approaches, whether or not earlier than surgical procedure or in the course of the postoperative interval.

The investigators acknowledged limitations of their evaluation, together with potential inaccuracies in well being file knowledge and uncertainty about whether or not sufferers stuffed or took their prescribed medicines.

Research co-author is Mahmoud Abdel-Rasoul, MS, MPH.